Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

NCT04544293 is registered in ClinicalTrials.gov with Savara Inc. as lead sponsor.

NCT NCT04544293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04544293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Lead sponsor
Savara Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 19, 2021
Completion date
May 30, 2027
Enrollment
164 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune pulmonary alveolar proteinosis